What is Cerus?
Headquartered in Concord, California, Cerus is a biomedical innovator dedicated to the development and commercialization of the INTERCEPT Blood System. This core technology represents a significant advancement in transfusion medicine, providing blood centers and hospitals with a robust method to inactivate pathogens in platelets and plasma. By integrating pathogen reduction into standard blood processing workflows, Cerus addresses a critical vulnerability in the global healthcare infrastructure. The company's market position is defined by its specialized focus on red blood cell safety and its ability to navigate complex regulatory environments to deliver life-saving medical devices. As a key player in the life sciences sector, Cerus remains at the forefront of blood safety innovation, continuously expanding its product pipeline to meet the evolving needs of clinical environments worldwide.
How much funding has Cerus raised?
Cerus has raised a total of $378.6M across 8 funding rounds:
Stock Offering
$21.3M
Debt
$10M
Debt
$30M
Debt
$40M
Debt
$90M
Stock Offering
$63.3M
Unspecified
$14M
Debt
$110M
Stock Issuance/Offering (1997): $21.3M with participation from Undisclosed
Debt (2010): $10M led by Oxford Finance Corporation
Debt (2014): $30M supported by Oxford Finance
Debt (2017): $40M featuring Oxford Finance Corporation
Debt (2019): $90M backed by MidCap Financial
Stock Issuance/Offering (2020): $63.3M with participation from Undisclosed
Unspecified (2020): $14M led by Biomedical Advanced Research and Development Authority
Debt (2026): $110M supported by MidCap Financial
Key Investors in Cerus
MidCap Financial
MidCap Financial is a specialty finance firm that provides tailored, flexible debt solutions to companies in the healthcare and life sciences sectors.
Oxford Finance Corporation
Oxford Finance is a specialty finance firm that offers flexible financial solutions to healthcare and life sciences companies worldwide.
Biomedical Advanced Research and Development Authority
A federal agency focused on the advanced research and development of medical countermeasures to protect the nation from health security threats.
What's next for Cerus?
With the successful closure of this major strategic investment, Cerus is well-positioned to accelerate its operational objectives. The company is expected to prioritize the expansion of its INTERCEPT Blood System, focusing on broader market penetration and the advancement of its red blood cell programs. This capital injection provides the necessary liquidity to support ongoing research and development, as well as the scaling of commercial operations to meet increasing demand for high-quality blood components. Looking ahead, Cerus will likely focus on strengthening its balance sheet while maintaining its leadership in the pathogen reduction market, ensuring that its technological advancements remain accessible to healthcare systems globally. The strategic deployment of these funds will be instrumental in driving long-term value for stakeholders and enhancing the safety profile of the global blood supply.
See full Cerus company page
